A5044912710- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Childhood Cancer Survivors' Quality of Life
- Gastrointestinal Tumor Research and Treatment
- Gestational Trophoblastic Disease Studies
- Cancer survivorship and care
- Gallbladder and Bile Duct Disorders
- Liver Disease Diagnosis and Treatment
- Inflammatory Bowel Disease
- Liver Disease and Transplantation
- Helicobacter pylori-related gastroenterology studies
- Liver Diseases and Immunity
- Intraperitoneal and Appendiceal Malignancies
- Pediatric Hepatobiliary Diseases and Treatments
- Gastroesophageal reflux and treatments
- Pituitary Gland Disorders and Treatments
- Ovarian cancer diagnosis and treatment
- Metastasis and carcinoma case studies
- Microscopic Colitis
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Health Systems, Economic Evaluations, Quality of Life
Hampshire Hospitals NHS Foundation Trust
2016-2025
King's College Hospital
2016-2025
Kings Health Partners
2014-2025
Basingstoke and North Hampshire Hospital
2011-2025
University of Winchester
2023-2024
European Neuroendocrine Tumor Society
2015-2023
National Health Service
2003-2022
King's College London
2015-2022
King's College - North Carolina
2010-2021
Ibero American University
2017-2018
These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from clinical committees British Gastroenterology, for Endocrinology, Association Surgeons Great Britain (and its Surgical Specialty Associations), Gastrointestinal Abdominal Radiology others. The authorship represents leaders various groups Society, but large amount work has carried out other specialists, many...
Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence available for second-line chemotherapy. The aim of this study was to determine benefit derived from FOLFOX (folinic acid, fluorouracil, oxaliplatin) in advanced cancer.
New epidemiological data come from a study performed in Argentina [2] , showing that g-NENs and d-NENs represent 6.9 2.0% of all digestive NENs, respectively.These are similar to the SEER data, where were found 8.7% enteric NENs [3] quite recent prospective Austrian by Niederle et al. [4] represented 5.6% NENs.The proportions with respect overall NEN rates do vary, however; 23% compared 6% 5% Canadian (Ontario) 7.4% Taiwanese [4][5][6][7] .These differences underline need for multicenter...
<h3>Background</h3> Clinicians use fibrosis in a liver biopsy to predict clinical outcomes of chronic disease. The performance non-invasive tests has been evaluated against histological assessment but as the reference standard would be ideal. enhanced (ELF) test was derived and validated large cohort patients shown have high diagnostic accuracy (area under curve (AUC)=0.80 95% CI 0.76 0.85) identification significant on biopsy. <h3>Objective</h3> To evaluate ELF predicting by following up...
The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria peptide receptor radionuclide therapy (PRRT) and defining the minimum requirements PRRT. It not guidelines' aim give recommendations on use specific radiolabelled somatostatin analogues PRRT as different are being used, their availability governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has...
ObjectiveThe objective of this study was to establish thresholds for clinical importance (TCIs) the five functioning and nine symptom scales European Organisation Research Treatment Cancer Quality Life Questionnaire Core 30 (EORTC QLQ-C30).Study Design SettingIn diagnostic study, cancer patients with mixed diagnoses treatments completed EORTC QLQ-C30 anchored questions in each domain terms their importance. The anchor questions, concerned limitations daily life, need help/care, worries...
The small intestine and pancreas are among the most frequent abdominal sites of origin neuroendocrine tumours. Distinctive features these forms represented by relatively low incidence wide heterogeneity in biological behaviour. In this light, it is difficult to standardize indications for surgery appropriate approach. It would be helpful surgeons managing patients with tumours have guidelines surgical treatment intestinal pancreatic proposed represent a consensus working group European...
We intended to identify the prognostic factors and results of interventions on patients with liver metastatic midgut carcinoids. Five institutions that are part United Kingdom Ireland neuroendocrine tumour (NET) group took in this study. Patients were included if they had histology proven NET origin metastases at time Clinical biochemical data collected retrospectively from hospital charts, pathology reports, radiology reports biochemistry records for each patient. Three hundred sixty The...
4003 Background: Level A evidence supports use of CisGem as first-line chemotherapy for ABC; no robust is available second-line chemotherapy. Methods: Pts diagnosed with ABC disease progression after prior were randomised (1:1) to either ASC+mFOLFOX or ASC. Randomisation was stratified by serum albumin levels ( < 35 vs ≥35 g/L), platinum sensitivity (determined from CisGem) and extent (locally advanced metastatic). ECOG PS0-1, adequate haematological, renal liver function, biliary...
The number of cancer survivors is growing steadily and increasingly, clinical trials are being designed to include long-term follow-up assess not only survival, but also late effects health-related quality life (HRQOL). Therefore it essential develop patient-reported outcome measures (PROMs) that capture the full range issues relevant disease-free survivors. objectives this project are: 1) a European Organisation for Research Treatment Cancer (EORTC) questionnaire captures physical, mental...
Abstract: In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide repeatable (octreotide in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults tumors of the digestive tract were randomly assigned (1:1) receive LAR (60 mg) or (40 every 28 days. Primary outcome was symptom control based on frequency bowel movements and flushing episodes. Objective tumor response secondary outcome....
Neuroendocrine neoplasia (NEN) incidence is rising internationally. We aimed to evaluate the epidemiology of NEN in England and examine changes survival over time.A retrospective, population-based study using nationally representative data between 1995 2018 from National Cancer Registry Analysis Service (NCRAS) was conducted on 63,949 tumours. Age-standardized calculated Office for Statistics (ONS) data. Overall (OS) Kaplan-Meier estimator. Multivariable analysis performed an accelerated...
The aim of the present guidance paper was to update previous ENETS guidelines on well-differentiated gastric and duodenal neuroendocrine tumours (NETs), providing practical for specialists in diagnosis management gastroduodenal NETs. Type II NETs, carcinomas (NECs), functioning NETs are not covered, since they will be discussed other papers.
Abstract This ENETS guidance paper, developed by a multidisciplinary working group, provides an update on the previous colorectal paper in different format. Guided key clinical questions practical advice diagnosis and management of neuroendocrine tumours (NET) caecum, colon, rectum is provided. Although covered one NET comprises heterogeneous group neoplasms. The most common rectal are often small G1 that can be treated adequate endoscopic resection techniques. Evidence from prospective...
Gastrinomas are neuroendocrine tumors (NETs), usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger-Ellison (ZES). ZES is characterized by gastric acid hypersecretion resulting severe acid-related peptic disease (peptic ulcer disease, PUD; gastro-esophageal reflux GERD) [1,2,3] diarrhea. In this section ZES, due to both duodenal pancreatic gastrinomas, will be covered together because clinically they similar [2, 3]. Specific points...
Carcinoid syndrome (CS) is associated with elevated serotonin, diarrhea, flushing, and increased risk of valvular heart disease. Many patients respond to somatostatin analogs initially, but response diminishes in most patients. Additional options are needed.To assess whether telotristat etiprate (TE) can reduce gastrointestinal symptoms CS urinary 5-hydroxyindoleacetic acid (u5-HIAA; a biomarker serotonin).A prospective, exploratory, dose-escalating 12-week, open-label, multicenter study TE...